The raised full-year guidance and accelerating subscription growth (+15% YoY) confirm durable demand in life sciences cloud. Watch for continued Vault CRM adoption and AI agent monetization as catalysts. The stock may gap up on the beat-and-raise; consider taking profits if the move exceeds 5-7% intraday given the stock's historical volatility post-earnings.
Price Chart
Executive Summary
Veeva reported FQ1 2027 results that exceeded guidance on all metrics: total revenue of $882.9M (+16% YoY) and GAAP diluted EPS of $1.57, beating the $2.24 consensus on a non-GAAP basis. The company raised its full-year FY2027 revenue guidance to $3,635-$3,645M (from $3,585-$3,600M) and non-GAAP EPS guidance to ~$9.05 (from ~$8.85), signaling accelerating momentum in its life sciences cloud business.
Key Financial Metrics
Key Facts
- Total revenues of $882.9M, up 16% YoY, above the $888.6M consensus (beat by 0.1%)
- Subscription revenues of $730.2M, up 15% YoY, driven by R&D and Quality Solutions ($392.3M, +19% YoY)
- GAAP diluted EPS of $1.57 vs $1.37 a year ago; non-GAAP diluted EPS of $2.24, in line with consensus
- Raised FY2027 revenue guidance to $3,635-$3,645M (from $3,585-$3,600M) and non-GAAP EPS to ~$9.05 (from ~$8.85)
- Q2 FY2027 guidance: revenue $902-$905M, non-GAAP EPS $2.21-$2.22
- Operating cash flow of $1.13B in the quarter, up 28% YoY
- Added 27 new Vault CRM customers in the quarter, now over 150 live; AI strategy advancing with Ostro, Vault AI, and Veeva Falcon
Financial Impact
Revenue beat by ~$0.3M vs consensus; raised FY guidance by ~$50M; non-GAAP EPS guidance raised by ~$0.20
Risk Factors
- Macroeconomic headwinds could slow biopharma IT spending
- Execution risk on AI agent rollout (Veeva Falcon, Vault AI) and customer adoption timelines
- Competition from Salesforce and other cloud vendors in life sciences vertical
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001393052-26-000022 |
| Document: veev-20260603.htm | 0001393052-26-000022 |
| Document: 0001393052-26-000022-index-headers.html | 0001393052-26-000022 |
| Document: 0001393052-26-000022-index.html | 0001393052-26-000022 |
| Document: 0001393052-26-000022.txt | 0001393052-26-000022 |
| 8-K Data (Synthetic) | 0001393052-26-000022 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 26, 2026 5w ago | Press Release | $282.13 $278.39 | ▼ −1.33% | ▼ −1.22% | $274.52 (−2.70%) |
Jun 3, 2026 17w ago | 8-K | $178.54 $192.74 | ▲ +7.96% | ▲ +9.58% | $274.52 (+53.76%) |
May 4, 2026 21w ago | DEFA14A | $170.18 $188.66 | ▲ +10.86% | ▲ +5.22% | $274.52 (+61.31%) |
Apr 20, 2026 23w ago | 8-K | $167.71 $163.85 | ▼ −2.30% | ▼ −7.21% | $274.52 (+63.69%) |
Mar 4, 2026 30w ago | 8-K | $195.27 $173.86 | ▼ −10.96% | ▼ −7.18% | $274.52 (+40.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access